Umbilical cord blood transplantation for non-malignant diseases.
Many factors, including lower risk of GVHD, rapid availability of 4/6-6/6 matched cord blood (CB) units and incremental gains in the outcomes, have led to an increasing use of CB transplantation (CBT) to treat many patients who lack fully matched adult BM donors. A large electronically searchable worldwide inventory of publicly banked CB units allows for quicker donor identification and selection. In this review, we examine the current status and cumulative experience of related and unrelated donor CBT for the treatment of non-malignant diseases, including hemoglobinopathies, BM failure syndromes, primary immunodeficiency diseases (PIDs) and inherited metabolic disorders (IMDs), and conclude that CBT offers a promising and effective therapy for these diseases. Future strategies to facilitate earlier diagnosis and to decrease transplant-related risks should further improve the short- and long-term outcomes. Every effort should be made to perform transplantation early in the course of disease before extensive damage to various tissues and organs ensues.
The Pediatric Blood and Marrow Transplant Program, Duke University Medical Center, Durham, NC 27710, USA. vinod.prasad@duke.edu
V K
VK
Prasad
J
J
Kurtzberg
D000818:Animals; D002986:Clinical Trials as Topic; D036101:Cord Blood Stem Cell Transplantation / Q000009:adverse effects; D006084:Graft Rejection / Q000628:therapy; D006453:Hemoglobinopathies / Q000628:therapy*; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000628:therapy*; D008661:Metabolism, Inborn Errors / Q000628:therapy*